Herbas VPB

Print
EN | LT
LT - USE OF TUMOR INFLITRATING LYMPHOCYTES FOR TREATING NSCLC PATIENTS REFRACTORY FOR ANTI-PD-1 ANTIBODY
EN - USE OF TUMOR INFILTRATING LYMPHOCYTES FOR TREATING NSCLC PATIENTS REFRACTORY FOR ANTI-PD-1 ANTIBODY

Legal status

Patent not validated

Bibliographic data
Indications of the International Patent Classification (IPC)
(51) INT.CL. A61K 35/17 (2015.01)
A61K 35/17 (2013.01)
A61K 45/06 (2006.01)
A61K 45/06 (2013.01)
C12N 5/0781 (2010.01)
C12N 5/0635 (2013.01)
C12N 5/0783 (2010.01)
C12N 5/0636 (2013.01)
A61P 35/00 (2006.01)
C12N2501/2302 (2013.01)
C12N2501/2315 (2013.01)
C12N2501/2321 (2013.01)
C12N2501/515 (2013.01)
C12N2502/11 (2013.01)
C12N 5/0638 (2013.01)
European patent
(11) Number of the document 3843759
(13) Kind of document T
(96) European patent application number 19856433.8
Date of filing the European patent application 2019-09-03
(97) Date of publication of the European application 2021-07-07
(45) Date of publication and mention of the grant of the patent 2024-02-14
(46) Date of publication of the claims translation
PCT application
(86) Number PCT/US2019/049384
Date 2019-09-03
PCT application publication
(87) Number WO 2020/096682
Date 2020-05-14
Priority applications
(30) Number Date Country code
201862725976 P 2018-08-31 US
201862726919 P 2018-09-04 US
Inventors
(72)
FARDIS, Maria , US
NATARAJAN, Arvind , US
Grantee
(73) Iovance Biotherapeutics, Inc. , 825 Industrial Road Suite 400, San Carlos, CA 94070, US
Title
(54) USE OF TUMOR INFLITRATING LYMPHOCYTES FOR TREATING NSCLC PATIENTS REFRACTORY FOR ANTI-PD-1 ANTIBODY
  USE OF TUMOR INFILTRATING LYMPHOCYTES FOR TREATING NSCLC PATIENTS REFRACTORY FOR ANTI-PD-1 ANTIBODY